|
|
|
|
|
|
|
|
As of September 30, 2016 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
Financial Assets | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Money market funds | $ | 334 | $ | — | $ | — | $ | 334 | ||||||||
Marketable investments: | ||||||||||||||||
Commercial paper | — | 8,620 | — | 8,620 | ||||||||||||
U.S. Treasury | 15,506 | — | 15,506 | |||||||||||||
U.S. agency securities | — | 11,804 | — | 11,804 | ||||||||||||
U.S. states and municipalities | — | 13,118 | — | 13,118 | ||||||||||||
Corporate bonds | — | 71,234 | — | 71,234 | ||||||||||||
Non-U.S. government debt securities | — | 5,693 | — | 5,693 | ||||||||||||
Total | $ | 15,840 | $ | 110,469 | $ | — | $ | 126,309 |
As of December 31, 2015 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
Financial Assets | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Commercial paper | $ | — | $ | 9,850 | $ | — | $ | 9,850 | ||||||||
Money market funds | 252 | — | — | 252 | ||||||||||||
Marketable investments: | ||||||||||||||||
Commercial paper | — | 22,332 | — | 22,332 | ||||||||||||
U.S. Treasury | 15,436 | — | — | 15,436 | ||||||||||||
U.S. agency securities | — | 21,464 | — | 21,464 | ||||||||||||
U.S. states and municipalities | — | 2,084 | — | 2,084 | ||||||||||||
Corporate bonds | — | 61,002 | — | 61,002 | ||||||||||||
Non-U.S. government debt securities | — | 6,939 | — | 6,939 | ||||||||||||
Total | $ | 15,688 | $ | 123,671 | $ | — | $ | 139,359 |
|
Allowance for Doubtful Accounts | September 30, 2016 | December 31, 2015 | ||||||
Balance at the beginning of the period | $ | 589 | $ | 602 | ||||
Charged to costs and expenses | 152 | (13 | ) | |||||
Deductions | (110 | ) | — | |||||
Balance at the end of the period | $ | 631 | $ | 589 |
September 30, 2016 | December 31, 2015 | |||||||
Prepaid Tax | $ | 3,321 | $ | 2,736 | ||||
Prepaid expenses | 5,236 | 4,706 | ||||||
Income tax receivable | 5,104 | 606 | ||||||
Other current assets | 5,004 | 1,304 | ||||||
Prepaid expenses and other current assets | $ | 18,665 | $ | 9,352 |
September 30, 2016 | ||||||||||||||||
Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial paper | $ | 8,621 | $ | 2 | $ | (3 | ) | $ | 8,620 | |||||||
U.S. Treasury | 15,488 | 18 | — | 15,506 | ||||||||||||
U.S. agency securities | 11,787 | 19 | (2 | ) | 11,804 | |||||||||||
U.S. states and municipalities | 13,129 | — | (11 | ) | 13,118 | |||||||||||
Corporate bonds | 71,113 | 133 | (12 | ) | 71,234 | |||||||||||
Non-U.S. government debt securities | 5,693 | 3 | (3 | ) | 5,693 | |||||||||||
Total | $ | 125,831 | $ | 175 | $ | (31 | ) | $ | 125,975 |
December 31, 2015 | ||||||||||||||||
Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial paper | $ | 22,328 | $ | 5 | $ | (1 | ) | $ | 22,332 | |||||||
U.S. Treasury | 15,459 | 4 | (27 | ) | 15,436 | |||||||||||
U.S. agency securities | 21,497 | 1 | (34 | ) | 21,464 | |||||||||||
U.S. states and municipalities | 2,086 | — | (2 | ) | 2,084 | |||||||||||
Corporate bonds | 61,188 | 3 | (189 | ) | 61,002 | |||||||||||
Non-U.S. government debt securities | 6,954 | 1 | (16 | ) | 6,939 | |||||||||||
Total | $ | 129,512 | $ | 14 | $ | (269 | ) | $ | 129,257 |
September 30, 2016 | ||||||||
Fair Value | Gross Unrealized Losses | |||||||
Commercial paper | $ | 4,223 | $ | (3 | ) | |||
US Agency securities | 1,999 | (2 | ) | |||||
U.S. States and Municipalities | 11,778 | (11 | ) | |||||
Corporate bonds | 15,740 | (12 | ) | |||||
Non-U.S. government debt securities | 4,474 | (3 | ) | |||||
Total | $ | 38,214 | $ | (31 | ) |
December 31, 2015 | ||||||||
Fair Value | Gross Unrealized Losses | |||||||
Commercial paper | $ | 4,746 | $ | (1 | ) | |||
U.S. Treasury | 12,453 | (27 | ) | |||||
U.S. agency securities | 13,475 | (34 | ) | |||||
U.S. states and municipalities | 2,084 | (2 | ) | |||||
Corporate bonds | 59,163 | (189 | ) | |||||
Non-U.S. government debt securities | 5,881 | (16 | ) | |||||
Total | $ | 97,802 | $ | (269 | ) |
September 30, 2016 | December 31, 2015 | ||||||
Fair Value | |||||||
Due in one year | $ | 94,388 | $ | 62,983 | |||
Due in one to five years | 31,587 | 66,274 | |||||
Total | $ | 125,975 | $ | 129,257 |
September 30, 2016 | December 31, 2015 | |||||||
Raw materials | $ | 10,900 | $ | 9,176 | ||||
Work in process | 2,991 | 2,746 | ||||||
Finished goods | 56,201 | 44,839 | ||||||
Inventories | $ | 70,092 | $ | 56,761 |
September 30, 2016 | December 31, 2015 | |||||||
Machinery and equipment | $ | 9,708 | $ | 8,559 | ||||
Furniture and fixtures | 3,112 | 2,091 | ||||||
Leasehold improvements | 2,384 | 1,564 | ||||||
Software | 1,020 | 666 | ||||||
Computers | 671 | 565 | ||||||
Construction in progress | 6,194 | 577 | ||||||
Total property and equipment | 23,089 | 14,022 | ||||||
Less: Accumulated depreciation and amortization | (6,865 | ) | (5,071 | ) | ||||
Property and equipment, net | $ | 16,224 | $ | 8,951 |
September 30, 2016 | December 31, 2015 | |||||||
Payroll and employee-related expenses | $ | 17,519 | $ | 13,653 | ||||
Sales return reserve | 2,995 | 3,247 | ||||||
Preclinical and clinical trial cost | 2,195 | 1,330 | ||||||
Deferred revenue | 345 | 526 | ||||||
Product warranty | 1,138 | 713 | ||||||
Sales tax payable | 578 | 531 | ||||||
Income tax payable | 400 | 308 | ||||||
Leasehold improvement expenditures | 2,093 | — | ||||||
Other accrued liabilities | 6,497 | 5,273 | ||||||
Total accrued liabilities | $ | 33,760 | $ | 25,581 |
September 30, 2016 | December 31, 2015 | |||||||
Balance at the beginning of the period | $ | 713 | $ | 314 | ||||
Provision for product warranty | 894 | 752 | ||||||
Settlements of product warranty claims | (469 | ) | (353 | ) | ||||
Balance at the end of the period | $ | 1,138 | $ | 713 |
|
|
Number of Shares | Weighted- Average Exercise Price | ||||||
Balance at December 31, 2015 | 3,755,345 | $ | 12.13 | ||||
Options exercised | (832,681 | ) | 3.45 | ||||
Options canceled | (15,925 | ) | 17.90 | ||||
Balance at September 30, 2016 | 2,906,739 | 14.58 |
Number of Shares | Weighted Average Grant Date Fair Value | ||||||
Unvested at December 31, 2015 | 849,571 | $ | 15.12 | ||||
Granted | 293,250 | 61.78 | |||||
Vested | (139,325 | ) | 17.68 | ||||
Canceled/Forfeited | (7,500 | ) | 19.77 | ||||
Unvested and expected to vest at September 30, 2016 | 995,996 | 28.47 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Cost of sales | $ | 83 | $ | 141 | $ | 742 | $ | 271 | ||||||||
Research and development | 251 | 100 | 790 | 282 | ||||||||||||
Sales, general and administrative | 3,930 | 1,269 | 9,268 | 4,573 | ||||||||||||
Total | $ | 4,264 | $ | 1,510 | $ | 10,800 | $ | 5,126 |
|
Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | |||||||||||||||||||||||
Marketable Investments | Currency Translation Adjustments | Total | Marketable Investments | Currency Translation Adjustments | Total | |||||||||||||||||||
Balance at beginning of the period | $ | 206 | $ | (2,785 | ) | $ | (2,579 | ) | $ | — | $ | (1,233 | ) | $ | (1,233 | ) | ||||||||
Other comprehensive income before reclassifications: | ||||||||||||||||||||||||
Unrealized (losses) gains—marketable investments | (178 | ) | — | (178 | ) | — | — | — | ||||||||||||||||
Foreign currency translation (losses) gains | — | (901 | ) | (901 | ) | — | (327 | ) | (327 | ) | ||||||||||||||
Income tax effect—benefit (expense) | 63 | 3 | 66 | — | 24 | 24 | ||||||||||||||||||
Net of tax | (115 | ) | (898 | ) | (1,013 | ) | — | (303 | ) | (303 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income to earnings: | ||||||||||||||||||||||||
Realized losses (gains)—marketable investments | 1 | — | 1 | — | — | — | ||||||||||||||||||
Income tax effect—(expense) benefit | (1 | ) | — | (1 | ) | — | — | — | ||||||||||||||||
Net of tax | — | — | — | — | — | — | ||||||||||||||||||
Net current-year other comprehensive (loss) income | (115 | ) | (898 | ) | (1,013 | ) | — | (303 | ) | (303 | ) | |||||||||||||
Balance at end of the period | $ | 91 | $ | (3,683 | ) | $ | (3,592 | ) | $ | — | $ | (1,536 | ) | $ | (1,536 | ) |
Nine Months Ended September 30, 2016 | Nine Months Ended September 30, 2015 | |||||||||||||||||||||||
Marketable Investments | Currency Translation Adjustments | Total | Marketable Investments | Currency Translation Adjustments | Total | |||||||||||||||||||
Balance at beginning of the period | $ | (163 | ) | $ | (1,952 | ) | $ | (2,115 | ) | $ | (220 | ) | $ | (644 | ) | $ | (864 | ) | ||||||
Other comprehensive income before reclassifications: | ||||||||||||||||||||||||
Unrealized gains (losses)—marketable investments | 401 | — | 401 | (162 | ) | — | (162 | ) | ||||||||||||||||
Foreign currency translation (losses) gains | — | (1,732 | ) | (1,732 | ) | — | (1,008 | ) | (1,008 | ) | ||||||||||||||
Income tax effect—(expense) benefit | (145 | ) | 1 | (144 | ) | 36 | 116 | 152 | ||||||||||||||||
Net of tax | 256 | (1,731 | ) | (1,475 | ) | (126 | ) | (892 | ) | (1,018 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income to earnings: | ||||||||||||||||||||||||
Realized (gains) losses—marketable investments | (3 | ) | — | (3 | ) | 541 | — | 541 | ||||||||||||||||
Income tax effect—benefit (expense) | 1 | — | 1 | (195 | ) | — | (195 | ) | ||||||||||||||||
Net of tax | (2 | ) | — | (2 | ) | 346 | — | 346 | ||||||||||||||||
Net current-year other comprehensive income (loss) | 254 | (1,731 | ) | (1,477 | ) | 220 | (892 | ) | (672 | ) | ||||||||||||||
Balance at end of the period | $ | 91 | $ | (3,683 | ) | $ | (3,592 | ) | $ | — | $ | (1,536 | ) | $ | (1,536 | ) |
|
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
United States | $ | 44,380 | $ | 35,394 | $ | 127,484 | $ | 89,364 | ||||||||
Japan | 8,859 | 5,420 | 21,589 | 14,030 | ||||||||||||
Other International | 13,948 | 9,602 | 41,139 | 28,285 | ||||||||||||
Total | $ | 67,187 | $ | 50,416 | $ | 190,212 | $ | 131,679 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Neuro | $ | 47,534 | $ | 36,309 | $ | 134,180 | $ | 102,363 | ||||||||
Peripheral Vascular | 19,653 | 14,107 | 56,032 | 29,316 | ||||||||||||
Total | $ | 67,187 | $ | 50,416 | $ | 190,212 | $ | 131,679 |
|
|
As of September 30, 2016 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
Financial Assets | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Money market funds | $ | 334 | $ | — | $ | — | $ | 334 | ||||||||
Marketable investments: | ||||||||||||||||
Commercial paper | — | 8,620 | — | 8,620 | ||||||||||||
U.S. Treasury | 15,506 | — | 15,506 | |||||||||||||
U.S. agency securities | — | 11,804 | — | 11,804 | ||||||||||||
U.S. states and municipalities | — | 13,118 | — | 13,118 | ||||||||||||
Corporate bonds | — | 71,234 | — | 71,234 | ||||||||||||
Non-U.S. government debt securities | — | 5,693 | — | 5,693 | ||||||||||||
Total | $ | 15,840 | $ | 110,469 | $ | — | $ | 126,309 |
As of December 31, 2015 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Fair Value | |||||||||||||
Financial Assets | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Commercial paper | $ | — | $ | 9,850 | $ | — | $ | 9,850 | ||||||||
Money market funds | 252 | — | — | 252 | ||||||||||||
Marketable investments: | ||||||||||||||||
Commercial paper | — | 22,332 | — | 22,332 | ||||||||||||
U.S. Treasury | 15,436 | — | — | 15,436 | ||||||||||||
U.S. agency securities | — | 21,464 | — | 21,464 | ||||||||||||
U.S. states and municipalities | — | 2,084 | — | 2,084 | ||||||||||||
Corporate bonds | — | 61,002 | — | 61,002 | ||||||||||||
Non-U.S. government debt securities | — | 6,939 | — | 6,939 | ||||||||||||
Total | $ | 15,688 | $ | 123,671 | $ | — | $ | 139,359 |
|
Allowance for Doubtful Accounts | September 30, 2016 | December 31, 2015 | ||||||
Balance at the beginning of the period | $ | 589 | $ | 602 | ||||
Charged to costs and expenses | 152 | (13 | ) | |||||
Deductions | (110 | ) | — | |||||
Balance at the end of the period | $ | 631 | $ | 589 |
September 30, 2016 | December 31, 2015 | |||||||
Prepaid Tax | $ | 3,321 | $ | 2,736 | ||||
Prepaid expenses | 5,236 | 4,706 | ||||||
Income tax receivable | 5,104 | 606 | ||||||
Other current assets | 5,004 | 1,304 | ||||||
Prepaid expenses and other current assets | $ | 18,665 | $ | 9,352 |
September 30, 2016 | ||||||||||||||||
Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial paper | $ | 8,621 | $ | 2 | $ | (3 | ) | $ | 8,620 | |||||||
U.S. Treasury | 15,488 | 18 | — | 15,506 | ||||||||||||
U.S. agency securities | 11,787 | 19 | (2 | ) | 11,804 | |||||||||||
U.S. states and municipalities | 13,129 | — | (11 | ) | 13,118 | |||||||||||
Corporate bonds | 71,113 | 133 | (12 | ) | 71,234 | |||||||||||
Non-U.S. government debt securities | 5,693 | 3 | (3 | ) | 5,693 | |||||||||||
Total | $ | 125,831 | $ | 175 | $ | (31 | ) | $ | 125,975 |
December 31, 2015 | ||||||||||||||||
Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||
Commercial paper | $ | 22,328 | $ | 5 | $ | (1 | ) | $ | 22,332 | |||||||
U.S. Treasury | 15,459 | 4 | (27 | ) | 15,436 | |||||||||||
U.S. agency securities | 21,497 | 1 | (34 | ) | 21,464 | |||||||||||
U.S. states and municipalities | 2,086 | — | (2 | ) | 2,084 | |||||||||||
Corporate bonds | 61,188 | 3 | (189 | ) | 61,002 | |||||||||||
Non-U.S. government debt securities | 6,954 | 1 | (16 | ) | 6,939 | |||||||||||
Total | $ | 129,512 | $ | 14 | $ | (269 | ) | $ | 129,257 |
September 30, 2016 | ||||||||
Fair Value | Gross Unrealized Losses | |||||||
Commercial paper | $ | 4,223 | $ | (3 | ) | |||
US Agency securities | 1,999 | (2 | ) | |||||
U.S. States and Municipalities | 11,778 | (11 | ) | |||||
Corporate bonds | 15,740 | (12 | ) | |||||
Non-U.S. government debt securities | 4,474 | (3 | ) | |||||
Total | $ | 38,214 | $ | (31 | ) |
December 31, 2015 | ||||||||
Fair Value | Gross Unrealized Losses | |||||||
Commercial paper | $ | 4,746 | $ | (1 | ) | |||
U.S. Treasury | 12,453 | (27 | ) | |||||
U.S. agency securities | 13,475 | (34 | ) | |||||
U.S. states and municipalities | 2,084 | (2 | ) | |||||
Corporate bonds | 59,163 | (189 | ) | |||||
Non-U.S. government debt securities | 5,881 | (16 | ) | |||||
Total | $ | 97,802 | $ | (269 | ) |
September 30, 2016 | December 31, 2015 | ||||||
Fair Value | |||||||
Due in one year | $ | 94,388 | $ | 62,983 | |||
Due in one to five years | 31,587 | 66,274 | |||||
Total | $ | 125,975 | $ | 129,257 |
September 30, 2016 | December 31, 2015 | |||||||
Raw materials | $ | 10,900 | $ | 9,176 | ||||
Work in process | 2,991 | 2,746 | ||||||
Finished goods | 56,201 | 44,839 | ||||||
Inventories | $ | 70,092 | $ | 56,761 |
September 30, 2016 | December 31, 2015 | |||||||
Machinery and equipment | $ | 9,708 | $ | 8,559 | ||||
Furniture and fixtures | 3,112 | 2,091 | ||||||
Leasehold improvements | 2,384 | 1,564 | ||||||
Software | 1,020 | 666 | ||||||
Computers | 671 | 565 | ||||||
Construction in progress | 6,194 | 577 | ||||||
Total property and equipment | 23,089 | 14,022 | ||||||
Less: Accumulated depreciation and amortization | (6,865 | ) | (5,071 | ) | ||||
Property and equipment, net | $ | 16,224 | $ | 8,951 |
September 30, 2016 | December 31, 2015 | |||||||
Payroll and employee-related expenses | $ | 17,519 | $ | 13,653 | ||||
Sales return reserve | 2,995 | 3,247 | ||||||
Preclinical and clinical trial cost | 2,195 | 1,330 | ||||||
Deferred revenue | 345 | 526 | ||||||
Product warranty | 1,138 | 713 | ||||||
Sales tax payable | 578 | 531 | ||||||
Income tax payable | 400 | 308 | ||||||
Leasehold improvement expenditures | 2,093 | — | ||||||
Other accrued liabilities | 6,497 | 5,273 | ||||||
Total accrued liabilities | $ | 33,760 | $ | 25,581 |
September 30, 2016 | December 31, 2015 | |||||||
Balance at the beginning of the period | $ | 713 | $ | 314 | ||||
Provision for product warranty | 894 | 752 | ||||||
Settlements of product warranty claims | (469 | ) | (353 | ) | ||||
Balance at the end of the period | $ | 1,138 | $ | 713 |
|
Number of Shares | Weighted- Average Exercise Price | ||||||
Balance at December 31, 2015 | 3,755,345 | $ | 12.13 | ||||
Options exercised | (832,681 | ) | 3.45 | ||||
Options canceled | (15,925 | ) | 17.90 | ||||
Balance at September 30, 2016 | 2,906,739 | 14.58 |
Number of Shares | Weighted Average Grant Date Fair Value | ||||||
Unvested at December 31, 2015 | 849,571 | $ | 15.12 | ||||
Granted | 293,250 | 61.78 | |||||
Vested | (139,325 | ) | 17.68 | ||||
Canceled/Forfeited | (7,500 | ) | 19.77 | ||||
Unvested and expected to vest at September 30, 2016 | 995,996 | 28.47 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Cost of sales | $ | 83 | $ | 141 | $ | 742 | $ | 271 | ||||||||
Research and development | 251 | 100 | 790 | 282 | ||||||||||||
Sales, general and administrative | 3,930 | 1,269 | 9,268 | 4,573 | ||||||||||||
Total | $ | 4,264 | $ | 1,510 | $ | 10,800 | $ | 5,126 |
|
Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | |||||||||||||||||||||||
Marketable Investments | Currency Translation Adjustments | Total | Marketable Investments | Currency Translation Adjustments | Total | |||||||||||||||||||
Balance at beginning of the period | $ | 206 | $ | (2,785 | ) | $ | (2,579 | ) | $ | — | $ | (1,233 | ) | $ | (1,233 | ) | ||||||||
Other comprehensive income before reclassifications: | ||||||||||||||||||||||||
Unrealized (losses) gains—marketable investments | (178 | ) | — | (178 | ) | — | — | — | ||||||||||||||||
Foreign currency translation (losses) gains | — | (901 | ) | (901 | ) | — | (327 | ) | (327 | ) | ||||||||||||||
Income tax effect—benefit (expense) | 63 | 3 | 66 | — | 24 | 24 | ||||||||||||||||||
Net of tax | (115 | ) | (898 | ) | (1,013 | ) | — | (303 | ) | (303 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income to earnings: | ||||||||||||||||||||||||
Realized losses (gains)—marketable investments | 1 | — | 1 | — | — | — | ||||||||||||||||||
Income tax effect—(expense) benefit | (1 | ) | — | (1 | ) | — | — | — | ||||||||||||||||
Net of tax | — | — | — | — | — | — | ||||||||||||||||||
Net current-year other comprehensive (loss) income | (115 | ) | (898 | ) | (1,013 | ) | — | (303 | ) | (303 | ) | |||||||||||||
Balance at end of the period | $ | 91 | $ | (3,683 | ) | $ | (3,592 | ) | $ | — | $ | (1,536 | ) | $ | (1,536 | ) |
Nine Months Ended September 30, 2016 | Nine Months Ended September 30, 2015 | |||||||||||||||||||||||
Marketable Investments | Currency Translation Adjustments | Total | Marketable Investments | Currency Translation Adjustments | Total | |||||||||||||||||||
Balance at beginning of the period | $ | (163 | ) | $ | (1,952 | ) | $ | (2,115 | ) | $ | (220 | ) | $ | (644 | ) | $ | (864 | ) | ||||||
Other comprehensive income before reclassifications: | ||||||||||||||||||||||||
Unrealized gains (losses)—marketable investments | 401 | — | 401 | (162 | ) | — | (162 | ) | ||||||||||||||||
Foreign currency translation (losses) gains | — | (1,732 | ) | (1,732 | ) | — | (1,008 | ) | (1,008 | ) | ||||||||||||||
Income tax effect—(expense) benefit | (145 | ) | 1 | (144 | ) | 36 | 116 | 152 | ||||||||||||||||
Net of tax | 256 | (1,731 | ) | (1,475 | ) | (126 | ) | (892 | ) | (1,018 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income to earnings: | ||||||||||||||||||||||||
Realized (gains) losses—marketable investments | (3 | ) | — | (3 | ) | 541 | — | 541 | ||||||||||||||||
Income tax effect—benefit (expense) | 1 | — | 1 | (195 | ) | — | (195 | ) | ||||||||||||||||
Net of tax | (2 | ) | — | (2 | ) | 346 | — | 346 | ||||||||||||||||
Net current-year other comprehensive income (loss) | 254 | (1,731 | ) | (1,477 | ) | 220 | (892 | ) | (672 | ) | ||||||||||||||
Balance at end of the period | $ | 91 | $ | (3,683 | ) | $ | (3,592 | ) | $ | — | $ | (1,536 | ) | $ | (1,536 | ) |
|
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
United States | $ | 44,380 | $ | 35,394 | $ | 127,484 | $ | 89,364 | ||||||||
Japan | 8,859 | 5,420 | 21,589 | 14,030 | ||||||||||||
Other International | 13,948 | 9,602 | 41,139 | 28,285 | ||||||||||||
Total | $ | 67,187 | $ | 50,416 | $ | 190,212 | $ | 131,679 |
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2016 | 2015 | 2016 | 2015 | |||||||||||||
Neuro | $ | 47,534 | $ | 36,309 | $ | 134,180 | $ | 102,363 | ||||||||
Peripheral Vascular | 19,653 | 14,107 | 56,032 | 29,316 | ||||||||||||
Total | $ | 67,187 | $ | 50,416 | $ | 190,212 | $ | 131,679 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|